Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
05/2010
05/27/2010US20100129354 Intranasal delivery of polypeptides and proteins
05/27/2010US20100129319 Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor
05/27/2010US20100129294 Nattokinase for degrading and reducing amyloid fibrils assoicated with alzheimer's disease, prion diseases and other amyloidoses
05/27/2010US20100129288 Gliomedin, Fragments Thereof and Methods of Using Same
05/27/2010DE102007014947B4 Stabilisierte wässrige Lösungen von Ergolinverbindungen The stabilized aqueous solutions of ergoline compounds
05/27/2010CA2744343A1 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine compounds useful as faah modulators and uses thereof
05/27/2010CA2744339A1 Method for treating parkinson's disease
05/27/2010CA2744308A1 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
05/27/2010CA2744307A1 Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
05/27/2010CA2744016A1 Treatment of amyotrophic lateral sclerosis
05/27/2010CA2744012A1 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives
05/27/2010CA2744000A1 Early treatment and prevention of increased muscle tonicity
05/27/2010CA2743967A1 Homeopathic composition comprising hypericum perforatum extract and essential oils for the treatment of neuropathic pain
05/27/2010CA2743959A1 Liposomal composition for convection-enhanced delivery to the central nervous centre
05/27/2010CA2743724A1 8-azabicyclo[3.2.1]oct-2-ene derivatives and their use as mono-amine neurotransmitter re-uptake inhibitors
05/27/2010CA2743584A1 Lactams as beta secretase inhibitors
05/27/2010CA2743562A1 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
05/27/2010CA2742946A1 Antioxidant
05/27/2010CA2741986A1 Method and apparatus for manure treatment
05/27/2010CA2741511A1 Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity
05/27/2010CA2739900A1 Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
05/26/2010EP2189537A1 Detection and treatment of schizophrenia
05/26/2010EP2189526A1 Antibody binding specifically to tdp-43 aggregate
05/26/2010EP2189475A2 Fibroblast growth factor-like polypeptides
05/26/2010EP2189449A1 Aminopyrazole amide derivative
05/26/2010EP2188288A1 Octahydro-pyrrolo[3,4-b]pyrrole n-oxides
05/26/2010EP2188285A1 Pyrazoloquinoline and pyrazolonaphthyridine derivatives as gaba alpha ligands
05/26/2010EP2188284A2 Tricyclic heterocyclic compounds as gaba a modulators
05/26/2010EP2188282A2 1,2-diamido-ethylene derivatives as orexin antagonists
05/26/2010EP2188272A2 Phenyl- and benzylthiazolylpiperazine derivatives for the treatment of neurodegenerative diseases
05/26/2010EP2188268A1 Substituted piperazinyl pyrazines and pyridines as 5-ht7 receptor antagonists
05/26/2010EP2188263A1 Benzimidazole derivatives used as fxr agonists
05/26/2010EP2188261A1 Therapeutic compounds
05/26/2010EP2188258A1 Substituted nicotinamide compounds and the use thereof in pharmaceutical products
05/26/2010EP2188245A1 Nitric oxide releasing derivatives of paracetamol
05/26/2010EP2188015A2 Use of salusin beta alone or in combination with octreotide as a therapeutic agent
05/26/2010EP2187956A2 Use of a laminin peptide as a therapeutic agent
05/26/2010EP2187952A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents
05/26/2010EP2187950A1 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
05/26/2010EP2187949A2 Use of glp-1 as a therapeutic agent
05/26/2010EP2187948A2 Use of a peptide as a therapeutic agent
05/26/2010EP2187947A2 Use of calcitonin as anti-angiogenic agent
05/26/2010EP2187946A1 Use of a peptide as a therapeutic agent
05/26/2010EP2187945A2 Use of a peptide as a therapeutic agent
05/26/2010EP2187934A1 Use of fertirelin and delta-endorphin as therapeutic agents
05/26/2010EP2187931A2 Use of a combination of cart peptides as a therapeutic agent
05/26/2010EP2187930A2 Trap-14 as a therapeutic agent
05/26/2010EP2187924A2 Use of a peptide as a therapeutic agent
05/26/2010EP2187917A2 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent
05/26/2010EP2187915A2 Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
05/26/2010EP2187909A1 Use of bpp-b as a therapeutic agent
05/26/2010EP2187901A2 Therapeutic use of neuropeptide ei and a acth 7-38 and compositions thereof
05/26/2010EP2187898A1 Use of the cyp46a1 gene for the treatment of alzheimer's disease
05/26/2010EP2187890A1 Method for reducing intracranial pressure
05/26/2010EP2187888A2 Bicyclic amides for enhancing glutamatergic synaptic responses
05/26/2010EP2187882A1 Treatment of progressive neurodegenerative disease with ibudilast
05/26/2010EP1874783B1 Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
05/26/2010EP1622881B1 Quinazolinone-derivatives and their use for preparation of pharmaceutical compositions having parp enzyme inhibitory effect
05/26/2010EP1603915B1 SUBSTITUTED 8 -PYRIDINYL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE AND 8 -PYRIMIDIN YL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES
05/26/2010EP1596809B1 Abeta binding molecules
05/26/2010EP1539137B1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
05/26/2010EP1537113B9 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
05/26/2010EP1461325B1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/26/2010EP1424998B1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
05/26/2010EP1370275B1 Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
05/26/2010EP1307225B1 Antagonists of cd30 or cd30l for use in treating auto-immune and chronic inflammatory conditions
05/26/2010EP1303495B1 Substituted 5-alkynyl pyrimidines having neurotrophic activity
05/26/2010EP1132383B1 Novel agarofuan derivatives, their preparation, pharmaceutical composition containing them and their use as medicine
05/26/2010CN1994159B Kidney-strengthening mind-refreshing tobacco liquid for electronic atomized cigarette
05/26/2010CN1974545B Long chain fatty acyl amide compound and its application
05/26/2010CN1969814B Nasal administered preparation of melatonin
05/26/2010CN1956983B 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
05/26/2010CN1922183B Nitrogenous fused heteroaromatic ring derivative
05/26/2010CN1897935B Use of rotigotine for treatment or prevention of dopaminergic neurone loss
05/26/2010CN1893934B Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases
05/26/2010CN1893932B Microemulsion preconcentrate comprising a renin inhibitor
05/26/2010CN1875997B Application of sundew in pharmaceutical preparation
05/26/2010CN1849117B Entry inhibitors of the HIV virus
05/26/2010CN1827107B Substained analgesia achieved with buprenorphine
05/26/2010CN1814301B Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
05/26/2010CN1803180B Medicine composition and its preparation method and quality control method
05/26/2010CN1799622B Mind-tranquilizing brain-replenishing soft capsule, its preparation process and quality control method
05/26/2010CN1794999B Remedy for nerve damage
05/26/2010CN1781545B Method for extracting herbal medicine
05/26/2010CN1726217B Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
05/26/2010CN1690057B Selenophen derivatives and their use for prevention and/or treatment of diseases relative to protein aging
05/26/2010CN1681811B Azolidinone-vinyl fused-benzene derivatives
05/26/2010CN1662642B Pasteurisation process for microbial cells and microbial oil
05/26/2010CN1656073B Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
05/26/2010CN1655762B Ibuprofen suspension
05/26/2010CN1646138B Novel therapeutical use of agonist ligands specific to G2A receptor
05/26/2010CN1642580B Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
05/26/2010CN1596113B Use of delta receptor agonist compound in preparing medicine for treating depression
05/26/2010CN1565441B Use of levobutylphthalide in prevention and cure of dementia
05/26/2010CN1512884B 阿立哌唑口服溶液 Aripiprazole Oral Solution
05/26/2010CN1489580B 咪唑衍生物 Imidazole derivatives
05/26/2010CN101715450A Azaindole derivatives as cftr modulators
05/26/2010CN101715449A Heterocyclic compounds and their methods of use
05/26/2010CN101715437A Stereoisomers propofol therapeutic compounds
05/26/2010CN101712720A Human antibodies that bind human TNF alpha
1 ... 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 ... 1833